Quarterly report pursuant to Section 13 or 15(d)

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

v3.21.2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE

 SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE

          As of
September 30,
2021
    As of
December 31,
2020
 
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
          (unaudited)        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       6,682       6,682  
BioPharma acquisition:                        
Trademarks     10       1,600       1,600  
Customer relationships     8       5,700       5,700  
                         
CLIA Lab     2.3       609       609  
                         
Total           $ 39,251     $ 39,251  
                         
Accumulated Amortization           $ (31,237 )   $ (27,900 )
                         
Net Carrying Value           $ 8,014     $ 11,351  
SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE

SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 

2021     2022     2023     2024     2025  
$ 1,112     $ 2,155     $ 2,099     $ 873     $ 873  
SCHEDULE OF GOODWILL CARRYING VALUE

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to September 30, 2021:

 

SCHEDULE OF GOODWILL CARRYING VALUE 

    Carrying  
    Amount  
Balance as of December 31, 2020   $ 8,433  
Adjustments     -  
Balance as of September 30, 2021   $ 8,433